Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches

2017/06/20 by Carlos González-Herrada, Sara Rodríguez-Martín, Lucía Cachafeiro +32 · 28 citations
Medicine · #Drug-Induced Adverse Reactions #Food Allergy and Anaphylaxis Research #Contact Dermatitis and Allergies

paper · doi:10.1016/j.jid.2017.05.022

Citations

• Comprehensive Survival Analysis of a Cohort of Patients with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

Cited by

• Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States
• Diagnosing and Managing Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017–2023
• Need for Trial Design Change in Epidermal Necrolysis (Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis): Example of Cyclosporine
• SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. [europepmc]
• Treatments for Severe Cutaneous Adverse Reactions. [europepmc]
• The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China. [europepmc]
• Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). [europepmc]
• Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. [europepmc]
• Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review. [europepmc]
• SJS/TEN 2019: From science to translation. [europepmc]
• Multidisciplinary care in Stevens-Johnson syndrome. [europepmc]
• Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. [europepmc]
• Assessment and Comparison of Performance of ABCD-10 and SCORTEN in Prognostication of Epidermal Necrolysis. [europepmc]
• Cyclosporine in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Experience from a Tertiary Care Centre of South Rajasthan. [europepmc]
• Recent Dermatological Treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Japan. [europepmc]
• Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study. [europepmc]
• Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Treated Successfully with Oral Cyclosporin: Case report and literature review. [europepmc]
• Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. [europepmc]
• Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis: The Role of Novel Inflammatory Markers and Proposed Revision of SCORTEN (Re-SCORTEN). [europepmc]
• Intravenous Immunoglobulin Combined With Corticosteroids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Propensity-Matched Retrospective Study in China. [europepmc]
• Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies. [europepmc]
• Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. [europepmc]
• Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity. [europepmc]
• A Review of the Systemic Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. [europepmc]
• Disease severity and status in Stevens-Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs. [europepmc]
• Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions. [europepmc]
• Severe cutaneous adverse reactions. [europepmc]
• Stevens-Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management. [europepmc]